deltatrials
Not Yet Recruiting PHASE2 NCT06391008

Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer

Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer: a Single Arm, Open Label, Phase II Clinical Study

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Conditions Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer
Interventions Albumin Paclitaxel Carboplatin Evoximab Pemetrexed Stereotactic radiotherapy
Updated 3 times since 2024 Last updated: Apr 25, 2024 Started: Apr 30, 2024 Primary completion: Dec 30, 2024 Completion: Jun 30, 2025

This PHASE2 trial investigates Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer and is currently actively recruiting participants. The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School leads this study, which shows 3 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

3 versions recorded

  1. Sep 2024 — Present [monthly]

    Not Yet Recruiting PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Not Yet Recruiting PHASE2

  3. May 2024 — Jul 2024 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Apr 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Data source: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.